← Therapeutics
Details checkedClinical trial listing onlyHistorical/discontinuedCheckedregistry
House Research Institute Famciclovir Study in Unilateral Meniere's Disease
Also known as: Famciclovir, Famvir, Treatment of Hearing Fluctuation in Unilateral Meniere's Disease, NCT01526408
Institution-led study
Sponsor / Institution
Institution-led study
Program Type
Therapeutic
Modality
Small Molecule
Stage
Phase 3
Status
Discontinued
Target Gene
—
Route / Mode
Oral
Confidence
84%
Status Confidence
Status needs checking
Evidence Strength
Needs more support
Last Reviewed
2026-06-10
Geography
United States
Population
adult, unilateral, meniere-disease
Trial IDs
1
Mechanism
Terminated Phase 3 randomized placebo-controlled study of oral famciclovir/Famvir for hearing fluctuation in unilateral Meniere's disease.
Indications
Notes
Verified as a terminated House Research Institute study with House Clinic listed as an industry collaborator. It should be treated as a historical study, not a current famciclovir hearing-loss program.
Evidence & Sources
1 structured sourcesclinicaltrials
Supports: canonicalName, aliases, company, allCompanies, isIndustrySponsored, programType, modality, mechanism...
IDs: NCT01526408
Key Events
Clinical Trials (1)
Data Checks
industry-collaborated-studyregistry-only-evidencehistorical-studygeneric-repurposing-study
Related Programs
Otarmeni by Regeneron
Company: Regeneron Pharmaceuticals · Gene Therapy · Approved
PEDMARK by Fennec Pharmaceuticals
Company: Fennec Pharmaceuticals · Small Molecule · Marketed
AK-OTOF by Eli Lilly and Akouos
Company: Eli Lilly and Company · Gene Therapy · Phase 2
SENS-401 (Arazasetron) by Sensorion
Company: Sensorion · Small Molecule · Phase 2
SENS-501 by Sensorion
Company: Sensorion · Gene Therapy · Phase 1/2
Rincell-1 by Rinri Therapeutics
Company: Rinri Therapeutics · Cell Therapy · Phase 1/2